ClearSEEK™ PIK3CA Panel: Advancing Breast Cancer Treatment and Research
Breast cancer, particularly the hormone receptor-positive (HR+)/HER2-negative (HER2-) type, is a major health concern. A key factor in this subtype of breast cancer is the PIK3CA gene, which is often mutated and linked to a poorer prognosis. The introduction of the ClearSEEK™ PIK3CA Panel marks an important step in breast cancer research and treatment, focusing on these mutations.
Understanding PIK3CA in Breast Cancer
PIK3CA mutations are notably common in advanced HR+/HER2- breast cancer. Detecting these mutations early is critical, as they can inform treatment decisions, particularly in clinical studies involving PI3Kα inhibitors. These inhibitors have shown potential in treating cancers with specific genetic profiles.
The ClearSEEK™ PIK3CA Panel specifically targets 20 variants in the PIK3CA gene that are associated with how well patients might respond to certain treatments. These include activating mutations that are recommended for focus by the National Comprehensive Cancer Network Guidelines.
Key Features of the ClearSEEK™ PIK3CA Panel
- Targeted Variant Detection: The panel zeroes in on 20 clinically relevant variants in the PIK3CA gene. This targeted approach ensures that the most impactful mutations are identified for treatment planning.
- High Sensitivity for Mutation Detection: It can identify mutations present in as low as 1% of the sample, which means it can pick up even small but significant genetic changes.
- Minimal DNA Requirements: The panel’s ability to work with just 10 ng of DNA is a major advantage, especially when sample sizes are small.
- Efficient and Fast: With just 1 hour of hands-on time and 8 hours total, the panel is a practical tool for busy labs.
Implications for Breast Cancer Treatment
The ClearSEEK™ PIK3CA Panel’s ability to provide detailed information about PIK3CA mutations has significant implications for breast cancer treatment. It offers valuable insights for clinicians in deciding whether PI3Kα inhibitors would be effective for a particular patient. This kind of targeted treatment approach is becoming increasingly important in oncology. The panel supports the move towards personalized medicine in breast cancer treatment. By understanding the specific genetic makeup of a tumor, treatments can be tailored more effectively to individual patients. This means potentially better outcomes and fewer side effects.
Conclusion
The ClearSEEK™ PIK3CA Panel is a development in the fight against breast cancer. By focusing on the PIK3CA gene and providing a detailed analysis of key mutations, it helps clinicians and researchers better understand and treat HR+/HER2- breast cancer. Its efficiency, sensitivity, and user-friendliness make it a valuable tool in both clinical and research settings. As breast cancer treatment continues to evolve towards more personalized approaches, tools like the ClearSEEK™ PIK3CA Panel will play a crucial role in ensuring that patients receive the most effective treatments based on their individual genetic profiles.
